Literature DB >> 27646947

Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update.

Abram Recht1, Elizabeth A Comen1, Richard E Fine1, Gini F Fleming1, Patricia H Hardenbergh1, Alice Y Ho1, Clifford A Hudis1, E Shelley Hwang1, Jeffrey J Kirshner1, Monica Morrow1, Kilian E Salerno1, George W Sledge1, Lawrence J Solin1, Patricia A Spears1, Timothy J Whelan1, Mark R Somerfield1, Stephen B Edge1.   

Abstract

Purpose A joint American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology panel convened to develop a focused update of the American Society of Clinical Oncology guideline concerning use of postmastectomy radiotherapy (PMRT). Methods A recent systematic literature review by Cancer Care Ontario provided the primary evidentiary basis. The joint panel also reviewed targeted literature searches to identify new, potentially practice-changing data. Recommendations The panel unanimously agreed that available evidence shows that PMRT reduces the risks of locoregional failure (LRF), any recurrence, and breast cancer mortality for patients with T1-2 breast cancer with one to three positive axillary nodes. However, some subsets of these patients are likely to have such a low risk of LRF that the absolute benefit of PMRT is outweighed by its potential toxicities. In addition, the acceptable ratio of benefit to toxicity varies among patients and physicians. Thus, the decision to recommend PMRT requires a great deal of clinical judgment. The panel agreed clinicians making such recommendations for individual patients should consider factors that may decrease the risk of LRF, attenuate the benefit of reduced breast cancer-specific mortality, and/or increase risk of complications resulting from PMRT. When clinicians and patients elect to omit axillary dissection after a positive sentinel node biopsy, the panel recommends that these patients receive PMRT only if there is already sufficient information to justify its use without needing to know additional axillary nodes are involved. Patients with axillary nodal involvement after neoadjuvant systemic therapy should receive PMRT. The panel recommends treatment generally be administered to both the internal mammary nodes and the supraclavicular-axillary apical nodes in addition to the chest wall or reconstructed breast.

Entities:  

Mesh:

Year:  2016        PMID: 27646947     DOI: 10.1200/JCO.2016.69.1188

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  45 in total

1.  Impact of Radiotherapy on Complications and Patient-Reported Outcomes After Breast Reconstruction.

Authors:  Reshma Jagsi; Adeyiza O Momoh; Ji Qi; Jennifer B Hamill; Jessica Billig; Hyungjin M Kim; Andrea L Pusic; Edwin G Wilkins
Journal:  J Natl Cancer Inst       Date:  2018-02-01       Impact factor: 13.506

2.  Personalized radiotherapy for invasive breast cancer in 2017 : National S3 guidelines and DEGRO and AGO recommendations.

Authors:  Frederik Wenz; Wilfried Budach
Journal:  Strahlenther Onkol       Date:  2017-06-19       Impact factor: 3.621

Review 3.  Individualization of post-mastectomy radiotherapy and regional nodal irradiation based on treatment response after neoadjuvant chemotherapy for breast cancer : A systematic review.

Authors:  David Krug; René Baumann; Wilfried Budach; Jürgen Dunst; Petra Feyer; Rainer Fietkau; Wulf Haase; Wolfgang Harms; Thomas Hehr; Marc D Piroth; Felix Sedlmayer; Rainer Souchon; Frederik Wenz; Rolf Sauer
Journal:  Strahlenther Onkol       Date:  2018-01-30       Impact factor: 3.621

4.  Integrating Radiosensitivity and Immune Gene Signatures for Predicting Benefit of Radiotherapy in Breast Cancer.

Authors:  Yi Cui; Bailiang Li; Erqi L Pollom; Kathleen C Horst; Ruijiang Li
Journal:  Clin Cancer Res       Date:  2018-06-19       Impact factor: 12.531

5.  Perspectives on Postmastectomy Radiation Therapy for Persistent Nodal Disease After Neoadjuvant Chemotherapy: Is Hindsight 20/20?

Authors:  Grace L Smith
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-11-01       Impact factor: 7.038

6.  Most Breast Cancer Patients with T1-2 Tumors and One to Three Positive Lymph Nodes Do Not Need Postmastectomy Radiotherapy.

Authors:  Shirin Muhsen; Tracy-Ann Moo; Sujata Patil; Michelle Stempel; Simon Powell; Monica Morrow; Mahmoud El-Tamer
Journal:  Ann Surg Oncol       Date:  2018-03-21       Impact factor: 5.344

7.  Individualized Prediction of Survival Benefit from Postmastectomy Radiotherapy for Patients with Breast Cancer with One to Three Positive Axillary Lymph Nodes.

Authors:  Ning Zhang; Jiashu Zhang; Hanwen Zhang; Ying Liu; Wenjing Zhao; Lijuan Wang; Bing Chen; Meena S Moran; Bruce G Haffty; Qifeng Yang
Journal:  Oncologist       Date:  2019-07-17

8.  Canada follows the US in the rise of bilateral mastectomies for unilateral breast cancer: a 23-year population cohort study.

Authors:  L Findlay-Shirras; I Lima; G Smith; M Clemons; A Arnaout
Journal:  Breast Cancer Res Treat       Date:  2020-10-30       Impact factor: 4.872

Review 9.  Overview of Breast Cancer Therapy.

Authors:  Tracy-Ann Moo; Rachel Sanford; Chau Dang; Monica Morrow
Journal:  PET Clin       Date:  2018-07

10.  Patient-Reported Satisfaction Following Radiation of Implant-Based Breast Reconstruction.

Authors:  Eva Thiboutot; Peter Craighead; Carmen Webb; Claire Temple-Oberle
Journal:  Plast Surg (Oakv)       Date:  2019-03-13       Impact factor: 0.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.